Biogen (BIIB) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.62
- Estimate
- $1.99
- Surprise
- +31.5%
- Revenue (period 2026-09-30)
- $2.80B
- Score at report (before → after)
- 5.2 → 5.4/10
Revenue source: xbrl.
How the report landed
Biogen (BIIB) beat the $1.99 estimate with adjusted EPS of $2.62 — a large 31.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.2/10) to Hold at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BIIB Hold at 5.4/10.
4 of the last 4 quarters beat the estimate; this quarter's +31.5% surprise compares with a +38.9% four-quarter average. Next scheduled report: 2027-02-05.
What supports the rating
- Strong earnings beat streak (4/4)
- Earnings estimates trending UP
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (4.2% away)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $250.04
- Stop
- $235.12
The stock trades at 108.6× trailing but 15.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
BIIB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $37.07B
- P/E (fwd)
- 15.4
- P/E (ttm)
- 108.6
- 52-week range
- $160.36–$261.00
- Off 52-week high
- 4.2%
- RSI (14)
- 50
- Volume vs avg
- 0.44×
- Score today
- 5.4/10